Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).

被引：16
|
作者：
Yarchoan, Mark [1 ]
Zhu, Qingfeng [2 ]
Durham, Jennifer N. [3 ]
Gross, Nicole [1 ]
Charmsaz, Soren [1 ]
Leatherman, James M. [4 ]
Zhang, Shu [1 ]
Popovic, Aleksandra [5 ]
Weiss, Matthew John [6 ]
Philosophe, Benjamin [7 ]
Burkhart, Richard A. [8 ]
Burns, William [9 ]
Wilt, Brad [7 ]
Sugar, Elizabeth [7 ]
Fertig, Elana J. [10 ]
Laheru, Dan [11 ]
Anders, Robert A. [2 ]
Jaffee, Elizabeth M. [10 ]
Ho, Won Jin [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins, Bloomberg Kimmel Inst Canc Immunotherapy, Dept Pathol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Northwell Hlth Canc Inst, Manhasset, NY USA
[7] Johns Hopkins, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Johns Hopkins Univ, Baltimore, MD USA
[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
    Su, Y.
    Lin, Y.
    Hsiao, C.
    Ou, D.
    Chen, S.
    Wu, Y.
    Lee, W.
    Lin, J.
    Hsu, C.
    Ho, M.
    Lu, L.
    Wu, T.
    Lai, S.
    Chao, Y.
    Chou, T.
    Yen, C.
    Chen, L.
    Shan, Y.
    Cheng, A.
    Hsu, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S141 - S141
  • [12] Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
    Shuming Zhang
    Long Yuan
    Ludmila Danilova
    Guanglan Mo
    Qingfeng Zhu
    Atul Deshpande
    Alexander T. F. Bell
    Jennifer Elisseeff
    Aleksander S. Popel
    Robert A. Anders
    Elizabeth M. Jaffee
    Mark Yarchoan
    Elana J. Fertig
    Luciane T. Kagohara
    [J]. Genome Medicine, 15
  • [13] Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
    Zhang, Shuming
    Yuan, Long
    Danilova, Ludmila
    Mo, Guanglan
    Zhu, Qingfeng
    Deshpande, Atul
    Bell, Alexander T. F.
    Elisseeff, Jennifer
    Popel, Aleksander S.
    Anders, Robert A.
    Jaffee, Elizabeth M.
    Yarchoan, Mark
    Fertig, Elana J.
    Kagohara, Luciane T.
    [J]. GENOME MEDICINE, 2023, 15 (01)
  • [14] Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy.
    Horne, Zachary D.
    Sun, Weijing
    Gibson, Michael K.
    Pennathur, Arjun
    Luketich, James D.
    Karlovits, Brian J.
    Heron, Dwight Earl
    Greenberger, Joel S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [15] Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Shin, Bang Sup
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kwon, Wooil
    Jang, Jin-Young
    Kim, Sun-Whe
    [J]. GUT AND LIVER, 2021, 15 (02) : 315 - 323
  • [16] Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
    Choi, Jin G.
    Nipp, Ryan D.
    Tramontano, Angela
    Ali, Ayman
    Zhan, Tiannan
    Pandharipande, Pari
    Dowling, Emily C.
    Ferrone, Cristina R.
    Hong, Theodore S.
    Schrag, Deborah
    Fernandez-Del Castillo, Carlos
    Ryan, David P.
    Kong, Chung Yin
    Hur, Chin
    [J]. ONCOLOGIST, 2019, 24 (07): : 945 - 954
  • [17] PROGNOSTIC FACTORS FOR PATIENTS WITH BORDERLINE RESECTABLE OR LOCALLY ADVANCED PANCREATIC CANCER RECEIVING NEOADJUVANT FOLFIRINOX
    Choi, Young Hoon
    Lee, Sang Hyub
    You, Min Su
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    [J]. GASTROENTEROLOGY, 2019, 156 (06) : S321 - S322
  • [18] Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Kang, Yoon-Koo
    Hou, Ming-Mo
    Yeo, Winnie
    Numata, Kazushi
    Chopra, Akhil
    Baakili, Adyb
    dela Cruz, Christine
    Zhao, Huanyu
    Yau, Thomas
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [19] FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma
    Yamamoto, S.
    Kato, K.
    Daiko, H.
    Kojima, T.
    Hara, H.
    Abe, T.
    Tsubosa, Y.
    Nagashima, K.
    Kitagawa, Y.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [20] Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).
    Xu, Li
    Zhang, Yaojun
    Wang, Xiaohui
    Shi, Mude
    Wang, Juncheng
    Tang, Yuhao
    Fu, Yizhen
    Zhou, Zhongguo
    Chen, Minshan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345